Staying Up-to-date
on OMEICOS
OMEICOS Therapeutics Provides Update on PMD-OPTION Phase 2a Clinical Study Evaluating OMT-28 in Primary Mitochondrial Disease
OMEICOS Therapeutics Receives 2.5 million Euros in Grant Funding Supporting OMT-28’s Development in Mitochondrial Diseases Through a Phase 2a Clinical Study
OMEICOS Therapeutics Announces Expansion of OMT-28 Clinical Development Program into Primary Mitochondrial Diseases
OMEICOS Therapeutics Appoints Dr Simon Russell as Chief Business Officer
OMEICOS Therapeutics Announces First-Dosing in Phase 2 Clinical Study Evaluating its Lead Program OMT-28 in Patients with Persistent Atrial Fibrillation
OMEICOS Therapeutics Strengthens Board of Directors with the Appointment of Christian Schetter
OMEICOS Therapeutics Closes €17m Series C Financing to Advance Lead Candidate OMT-28 Towards Pivotal Trials in Atrial Fibrillation
OMEICOS Therapeutics Announces Compelling First-in-Human Data on Lead Compound OMT-28 and Prepares Phase 2 Trial in Atrial Fibrillation
Alexander Gebauer Joins Executive Board of OMEICOS Therapeutics and Named CEO and Chairman of OMEICOS Ophthalmics
OMEICOS Announces Formation of Inaugural Clinical Advisory Board
OMEICOS Secures Extension of Series B Financing Round to Expand its Technology into Ophthalmology
OMEICOS Secures Continued BMBF Support with New €1.7M Research Grant to Advance its Novel Approach to Treat Cardiovascular Diseases
